

Index

- acute bacterial meningitis (ABM) and stroke
 case presentation, 125–129
 cerebral spinal fluid (CSF), 130
 cerebrovascular event
 frequency, 129
 clinical features, 130
 neuropathology, 130
 stroke frequency, 129–130
 treatment, 131
- Alzheimer's disease (AD), acute bacterial meningitis (ABM) and stroke, 103–105
- amphetamines. *See* illicit drug-related stroke
- anabolic steroids. *See* illicit drug-related stroke
- angiography
 computed tomography angiography (CTA), 5
 digital subtraction angiography (DSA), 5–6, 8, 9
 fibromuscular dysplasia, 218
 flat detector CT angiography (FDCTA), 6, 7
 MR angiography (MRA), 5
- anticholinergic medication and stroke, 188
- antidepressants and stroke, 188–189
- antiphospholipid antibody syndrome (APS) and stroke
 case presentation, 151–152
 clinical manifestations, 154
 definition and clinical features, 154
 diagnosis, 155
 diagnostic algorithm, 152
 differential diagnosis, 155
 therapy, 155–156
- Behçet's syndrome (BS) and stroke
 case presentation, 72–73
 clinical presentation, 75
 defined, 74–75
 diagnostic algorithm, 74
 neurological manifestations, 75
 prognosis, 77
 treatment, 77–78
- Behçet's syndrome (BS) and stroke, classification
 parenchymal (p-NBS), 76
 vascular involvement, 76–77
- bone disorders and stroke
 case presentation, 336–339
 epidemiology, 339
- bone disorders and stroke complications
 fat embolism syndrome, 341
 fibrocartilaginous embolism, 341
 orthopedic procedures, 341
- bone disorders and stroke, types
 bone tumors, 340–341
 osteochondromas, 340
 osteoporosis, 339
 osteosarcoma, 341
 skeletal abnormalities, 340
 skull disorders, 339
- CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy)
 background, 237
 case presentation, 234–236
 definitions, 236–237
- Call–Fleming syndrome. *See* retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations (RVCL-S) and stroke
- Camurati–Engelmann disease and stroke, 340
- cancer and stroke
 case presentation, 179–180
 clinical features, 182–183
 diagnostic algorithm, 181
 imaging, 182
 treatment, 182
- cannabis. *See* illicit drug-related stroke
- CARASIL (cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy)
 background, 238
 case presentation, 234–236
 definitions, 236–237
- cardioembolism types
 infective endocarditis (IE), 287–291
 patent foramen ovale (PFO), 281–286
- carotid artery dissection and stroke
 case presentation, 326–328
 clinical presentation, 329
 epidemiology, 328–329
 imaging, 329
 risk factors, 329
 treatment, 329–330
- cerebral amyloid angiopathy (CAA), 103–105
- cerebral amyloid angiopathy (CAA) and stroke
 case presentation, 314
 classification, 316
 clinical presentation and imaging, 316
 diagnostic criteria, 317, 318–319, 320
 epidemiology and risk factors, 318
 imaging, 319–320
 management, 318, 320
- cerebral amyloid-related disease types
 Alzheimer's disease (AD), 103–105
 cerebral amyloid angiopathy (CAA), 103–105
- cerebral amyloid-related diseases
 case presentation, 99–101
 diagnostic algorithm, 101

- cerebral venous sinus thrombosis (CVST) and stroke
 case presentation, 331–332
 classification stages, 334
 clinical features, 334
 clinical presentation, 334
 diagnostic criteria, 334
 epidemiology, 333–334
 risk factors, 335
 treatment, 335
- cerebral venous thrombosis during pregnancy, 303
- cervical artery dissection (CAD) and migraine diagnosis, 308
 and migraine mechanisms, 308
- Chagas disease and stroke
 case presentation, 147–148
 defined, 148
 diagnostic algorithm, 148
 etiology, 149
 incidence, 148–149
 treatment, 149
- childhood arterial ischemic stroke (CASCADE) classification, 142
- Churg–Strauss syndrome. *See* eosinophilic granulomatosis with polyangiitis (EPGA) and stroke
- cocaine. *See* illicit drug-related stroke
- Cogan syndrome (CS) and stroke
 case presentation, 60–61
 clinical features, 64
 clinical presentation, 61, 64
 defined, 63–64
 diagnosis, 64
 differential diagnosis, 63, 64
 laboratory tests, 62
 neurological manifestations, 64
 treatment, 63, 64–65
- computed tomography angiography (CTA), 5
- computed tomography (CT) Eales disease, 59
 isolated central nervous system vasculitis (ICNSV), 5
- craniosynostosis and stroke, 339
- cysticercotic encephalitis, 135
- digital subtraction angiography (DSA), 5–6, 8, 9
- disseminated intravascular coagulation (DIC) and stroke. *See also* Moschowitz syndrome and stroke
 clinical features, 171
 defined, 171
 diagnosis, 171
 neurological manifestations, 171–172
 pathogenesis, 171
 treatment, 172
- dolichoectasia, 324
- DREAM center, 145
- drug-related stroke
 illicit, 190
 medication, 185–189
- Eagle syndrome and stroke
 case presentation, 343
 classification, 345, 346
 diagnosis, 345, 347
 epidemiology, 345, 346
 etiology, 346
 management, 345, 347–348
 pathophysiology, 346
 types, 346–347
- Eales disease and stroke
 case presentation, 54–55
 clinical presentation, 58
 defined, 57–58
 diagnosis, 58
 diagnostic algorithm, 56
 imaging, 59
 treatment, 59
- eclampsia during pregnancy and stroke
 case report, 299–300
 cerebral venous thrombosis, 303
 clinical presentation, 301
 defined, 301
 epidemiology, 300
 imaging, 301–302
 intracerebral hemorrhage (ICH), 303
 ischemic stroke, 302
 pre-eclampsia, 301–302
 stroke rate, 302
 stroke risk, 302
- Ecstasy. *See* illicit drug-related stroke
- Ehlers–Danlos syndrome and stroke
 case presentation, 199–200
 clinical presentation, 201
 complications, 201–202
 defined, 201
 diagnostic criteria, 201–202
 differential diagnosis, 202–205
 treatment, 202
 vascular complications, 201
- eosinophilic granulomatosis with polyangiitis (EPGA) and stroke
 case presentation, 28–30
 classification, 32
 clinical features, 30–31
 complications, 31
 diagnosis, 31–32
 evolving phases, 31
 five-factors-score for assessment of prognosis, 32
 treatment, 32–33
- essential thrombocytopenia (ET) and stroke, 165
- extraparenchymal neurocysticercosis, 135
- Fabry disease and stroke
 case presentation, 246–248
 diagnosis delay, 250–251
 diagnostic criteria, 249–250
 epidemiology, 249
 treatment, 250
- fat embolism syndrome, 341
- fibrocartilaginous embolism, 341
- fibromuscular dysplasia and stroke
 case presentation, 212–213
 clinical presentation, 218
 diagnosis, 218
 epidemiology, 217–218
 follow-up, 219
 treatment, 218–219
- five-factors-score for assessment of prognosis of eosinophilic granulomatosis with polyangiitis (EPGA), 32
- flat detector CT angiography (FDCTA), 6, 7

- fusiform aneurysms and stroke
 case presentation, 321–323
 clinical presentation, 324
 defined, 324
 diagnostic criteria, 324
 management, 325
- genetic conditions and stroke, types
 CADASIL and CARASIL, 234–238
 Ehlers–Danlos syndrome, 199–205
 Fabry disease, 246–251
 fibromuscular dysplasia, 212–219
 hereditary hemorrhagic telangiectasia (HHT), 228–233
 Marfan syndrome, 206–211
 Menkes disease, 262–266
 mitochondrial diseases (MELAS), 253–261
 neurofibromatosis type 1, 220–226
 organic acid disorders, 271–278
 retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations (RVCL-S), 240–245
 Tangier disease, 267–270
 giant cell arteritis (GCA) and stroke
 case presentation, 10–12
 clinical features, 12
 diagnosis, 12
 management, 13–14
 treatment, 13
- glutaric aciduria type 1 (GAI) and stroke
 clinical presentation, 275–276
 pathophysiology, 276–277
- granulomatosis with polyangiitis (GPA) and stroke
 case presentation, 34–35
 clinical features, 38
 complications, 38
 incidence, 38
 mortality rate, 38
 treatment, 38
- Henoch–Schönlein purpura.
See immunoglobulin A vasculitis and stroke
- hereditary hemorrhagic telangiectasia (HHT) and stroke
 case presentation, 228–229
 clinical features, 232
 clinical presentation, 230, 232
 diagnosis, 232
 epidemiology, 231
 genetic testing, 231
 prognosis, 232
 therapy, 231, 233
- heroin. *See* illicit drug-related stroke
- HIV disease in sub-Saharan Africa and stroke
 case presentation, 141–142
 differential diagnosis, 143
 DREAM center, 145
 education and training, 145
 geography, 142–143
 hypertensive patient percentage, 144
 incidence, 143
 prevalence, 144–145
 treatment, 145
- hormone replacement therapy (HRT) and stroke, 187
- hyperhomocysteinemia and stroke
 case presentation, 157–158
 clinical features, 160
 clinical presentation, 157–158
 defined, 159–160
 diagnosis, 157–158
 homocysteinemia, 160
 incidence, 160
 management, 157–158
 stroke frequency, 160
- hyperviscosity syndrome (HVS) and stroke
 case presentation, 162–163
 clinical features, 166
 clinical manifestations, 166
 defined, 164
 diseases associated with, 165
 elevated blood viscosity, 164–165
 essential thrombocytopenia (ET), 165
 leukemias, 165
 polycythemia vera (PV), 165
- sickle cell disease (SCD), 165–166
 treatment, 166–167
- illicit drug-related stroke
 case presentation, 190
 imaging and diagnostic work-up, 197
 incidence, 192–197
 therapy, 197
- immunoglobulin A vasculitis and stroke
 background, 176
 case presentation, 174
 clinical presentation, 177
 clinical symptoms, 176–177
 diagnosis and treatment algorithm, 175–176
 imaging, 177
 management, 177–178
 neurological manifestations, 177
 outcomes, 178
 pathophysiology, 176
- infectious and postinfectious vasculitis, types
 acute bacterial meningitis (ABM), 129–131
 Chagas disease, 148–149
 HIV disease, 142–145
 Lyme disease (LD), 113–117
 meningovascular syphilis, 108–110
 neurocysticercosis (NCC), 134–136
 tuberculosis meningitis (TBM), 121–124
 varicella zoster virus (VZV), 137–139
- infective endocarditis (IE) and stroke
 case presentation, 287–288
 diagnosis, 290
 epidemiology, 290
 neurological complications, 290
 risk factors, 290
 treatment, 290–291
- inflammatory bowel diseases (IBD) and stroke
 case presentation, 92–93
 defined, 97
 diagnostic algorithm, 93
 gastrointestinal manifestations, 97
 TAK, 97–98

- inflammatory conditions and stroke, case presentation, 1–2
- inflammatory conditions and stroke, types of
- Behçet's syndrome (BS), 74–78
- cerebral amyloid-related diseases, 101–105
- Cogan syndrome (CS), 61–65
- Eales disease, 56–59
- eosinophilic granulomatosis with polyangiitis (EPGA), 30–33
- giant cell arteritis (GCA), 12–14
- granulomatosis with polyangiitis (GPA), 38–39
- inflammatory bowel diseases (IBD), 93–98
- isolated central nervous system vasculitis (ICNSV), 4–7
- lymphomatoid granulomatosis (LG), 41–43
- polyarteritis nodosa (PAN), 26–27
- sarcoidosis, 87–91
- Sjögren syndrome, 80–83
- Susac syndrome (SS), 47–48
- systemic lupus erythematosus (SLE), 69–70
- Takayasu arteritis (TAK), 19–22
- Vogt–Koyanagi–Harada disease (VKH), 51–53
- intracerebral hemorrhage (ICH) and stroke during pregnancy, 303
- intraparenchymal neurocysticercosis, 135
- ischemic stroke in pregnancy
- eclampsia, 302
- etiology, 302
- peripartum cardiomyopathy, 302
- postpartum benign angiopathy, 302
- risk factors, 302
- isolated central nervous system vasculitis (ICNSV) and stroke
- clinical features, 4
- mortality causes, 4
- pathogenesis and etiology, 4
- isolated central nervous system vasculitis (ICNSV)
- imaging
- biopsy evaluation, 6
- computed tomography (CT), 5
- CT angiography (CTA), 5
- diagnostic criteria, 6
- digital subtraction angiography (DSA), 5–6, 8, 9
- flat detector CT angiography (FDCTA), 6, 7
- magnetic resonance imaging (MRI), 4–5, 8
- MR angiography (MRA), 5
- MR venography (MRV), 5
- treatment, 6–7
- vessel-wall imaging (VWI) MR technique, 5, 8
- leukemias and stroke, 165
- LSD. *See* illicit drug-related stroke
- Lyme disease (LD) and stroke
- antibiotic treatment, 114
- case presentation, 112–113
- defined, 114
- diagnosis, 116
- diagnostic algorithm, 113
- pathophysiology, 114–115
- treatment, 116–117
- Lyme disease (LD) stages
- early, 115
- late, 115–116
- lymphomatoid granulomatosis (LG) and stroke
- case presentation, 40
- classification, 42
- clinical features, 42
- clinical presentation, 41, 42
- diagnostic algorithm, 41
- histological analysis, 42
- imaging, 43
- management, 43
- physiopathology, 42
- magnetic resonance imaging (MRI)
- Eales disease, 59
- isolated central nervous system vasculitis (ICNSV), 4–5, 8
- lymphomatoid granulomatosis (LG), 43
- Moschowitz syndrome, 170
- organic acid disorders and stroke, 276
- tuberculosis meningitis (TBM), 123
- marble bone disease, 339
- Marfan syndrome and stroke
- case presentation, 206–207
- clinical features, 208–209
- defined, 207–208
- diagnosis, 209–211
- differential diagnosis, 209
- epidemiology, 209
- pathophysiology, 209
- prognosis, 211
- treatment, 211
- medication and stroke
- anticholinergic, 188
- antidepressants and non-steroidal anti-inflammatory (NSAIDs), 188–189
- case presentation, 185–186
- controversial nature of, 187
- hormone replacement therapy (HRT), 187
- testosterone replacement (TRT), 187–188
- meningovascular syphilis and stroke
- case presentation, 107
- cerebral spinal fluid (CSF), 109
- clinical presentation, 109
- diagnosis, 109–110
- diagnostic algorithm, 108
- imaging, 109
- incidence, 108–109
- treatment, 110
- Menkes disease and stroke
- case presentation, 262
- diagnostic algorithm, 263
- diagnostic criteria, 263–266
- epidemiology, 263
- methylmalonic aciduria (MMA) and stroke
- clinical presentation, 277
- etiology, 277
- migraines and stroke
- background, 306–307
- case presentation, 305–306
- cervical artery dissection (CAD) diagnosis, 308

- cervical artery dissection (CAD) mechanisms, 308
- mitochondrial diseases (MELAS) and stroke
 case presentation, 253–256
 clinical presentation, 259–260
 diagnosis, 259
 diagnostic criteria, 259
 epidemiology, 258–259
 pathogenesis, 260
 pathophysiology, 259
 treatment, 260–261
- Moschowitz syndrome and stroke. *See also* disseminated intravascular coagulation (DIC) and stroke
 case presentation, 168–171
 clinical features, 173
 clinical presentation, 172
 defined, 172
 imaging, 172–173
 neurological manifestations, 172
 pathophysiology, 172
 plasmapheresis, 173
- moyamoya disease (MMD) and stroke
 case presentation, 309
 in children, 225
 classification and diagnosis, 312–313
 clinical presentation, 312
 epidemiology, 312
 etiology, 312
 pathophysiology, 312
 treatment, 313
- MR angiography (MRA), 5
 MR venography (MRV), 5
- neuroborreliosis. *See* Lyme disease (LD) and stroke
- neurocysticercosis (NCC) and stroke
 case presentation, 132–133
 clinical manifestations, 134–135
 diagnostic algorithm, 133
 diagnostic criteria, 135
 differential diagnosis, 135
 etiology, 134
 incidence, 134
 treatment, 134, 135
 types, 135
- neurofibromatosis type 1 and stroke
 case presentation, 220–222
 clinical features and incidence, 223
- neurofibromatosis type 1 and stroke diagnosis
 algorithm, 223
- central nervous system abnormalities, 224–225
 clinical presentation, 224
 epileptic seizures, 225
 genetics, 225–226
 imaging, 226
 management, 226
 ophthalmologic features, 224
 vascular abnormalities, 225
- non-steroidal anti-inflammatory drugs (NSAIDs) and stroke, 188–189
- ocular neurocysticercosis, 135
- organic acid disorders and stroke
 case presentation, 271
 clinical features, 273
 diagnosis, 273–274
 epidemiology, 273
 imaging, 275–276
 metabolic stroke and, 273
- organic acid disorders and stroke, treatment
 acute decompensation prevention, 277–278
 chronic monitoring, 278
- organic acid disorders, types of
 glutaric aciduria type 1 (GAI), 275–277
 methylmalonic aciduria (MMA), 277
 propionic aciduria, 277
- osteochondromas and stroke, 340
- osteopetrosis and stroke, 339
- osteoporosis and stroke, 339
- osteosarcoma and stroke, 341
- Paget's disease and stroke, 339
- patent foramen ovale (PFO) and stroke
 case presentation, 281–285
 clinical features, 285
 diagnosis, 286
 diagnosis difficulties, 285
- hemorrhage, 285
 imaging, 285
 paradoxical embolism (PDE), 285–286
 patent foramen ovale (PFO), 285–286
 role of, 286
 treatment, 286
- peripartum cardiomyopathy and stroke, 302
- plasmapheresis
 HVS, 166–167
 Moschowitz syndrome, 173
- polyarteritis nodosa (PAN) and stroke
 case presentation, 24–25
 classification, 27
 clinical features, 27
 diagnostic algorithm, 27
 manifestation, 27
 treatment, 27
- polycythemia vera (PV) and stroke, 165
- postpartum benign angiopathy, 302
- pre-eclampsia during pregnancy and stroke
 clinical presentation, 301
 defined, 301
 imaging, 301–302
 intracerebral hemorrhage (ICH), 303
- primary systemic vasculitis, types
 giant cell arteritis (GCA), 12–14
 granulomatosis with polyangiitis (GPA), 38–39
 lymphomatoid granulomatosis (LG), 41–43
 polyarteritis nodosa (PAN), 26–27
 Susac syndrome (SS), 47–48
 Takayasu arteritis (TAK), 19–22
 Vogt–Koyanagi–Harada disease (VKH), 51–53
- propionic aciduria and stroke, 277
- retinal periphlebitis. *See* Eales disease and stroke

- retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations (RVCL-S) and stroke case presentation, 240–243 diagnosis, 244 diagnostic criteria, 243–244 treatment, 244–245
- reversible cerebral vasoconstriction syndrome (RCVS) and stroke case presentation, 293–295 clinical presentation, 296 complications, 296 differential diagnosis, 297 etiology, 295 imaging, 296–297 pathophysiology and triggers for, 295–296 postpartum benign angiopathy, 302 treatment, 297
- sarcoidosis and stroke case presentation, 85–86 clinical features, 89 clinical presentation, 89 defined, 89 diagnosis, 90 diagnostic algorithm, 86 treatment, 90
- sickle cell disease (SCD) and stroke, 165–166
- Sjögren syndrome and stroke case presentation, 79–80 classification, 80 defined, 82 diagnosis, 83 diagnostic algorithm, 80 imaging, 83 neurological manifestations, 82 neurological symptoms, 82–83 pathogenesis, 82 therapy, 83
- skeletal abnormalities and stroke, types Camurati–Engelmann disease, 340 spondyloepiphyseal dysplasia congenita, 340
- skull disorders and stroke, types
- craniosynostosis, 339 osteopetrosis, 339 Paget’s disease, 339
- spinal neurocysticercosis and stroke, 135
- spondyloepiphyseal dysplasia congenita and stroke, 340
- Susac syndrome (SS) and stroke case presentation, 45–47 classification, 47–48 defined, 47 diagnosis, 48 diagnostic algorithm, 47 etiology, 47 treatment, 48
- systemic lupus erythematosus (SLE) and stroke case presentation, 66–67 defined, 69–70 diagnostic algorithm, 67 pathogenesis, 70 stroke and CNS related to, 70
- Takayasu arteritis (TAK) and stroke case presentation, 17–19 diagnostic algorithm, 19 diagnostic criteria, 19–21 differential diagnosis, 21–22 imaging, 21 inflammatory bowel diseases (IBD) and, 97–98 therapy, 22
- Tangier disease and stroke case presentation, 267 clinical presentation, 269 diagnostic algorithm, 267–269 differential diagnosis, 270 pathophysiology, 269 research findings, 269 therapy, 269–270
- testosterone replacement therapy (TRT) and stroke, 187–188
- thrombotic thrombocytopenic purpura (TTP). *See* Moschowitz syndrome and stroke
- transesophageal echocardiography (TEE), 286
- tuberculosis meningitis (TBM) and stroke case presentation, 119–120
- diagnosis, 123 diagnostic algorithm, 121 incidence and mortality, 122 neurological manifestations, 123 stroke frequency, 122–123 treatment, 123
- varicella zoster virus (VZV) and stroke case presentation, 137 clinical features, 139 stroke and cerebral venous thrombosis complications from, 137–138 treatment, 139
- vasculitis secondary to systemic disease, types Behçet’s syndrome (BS), 74–78 inflammatory bowel diseases (IBD), 93–98 sarcoidosis, 87–91 Sjögren syndrome, 80–83 systemic lupus erythematosus (SLE), 69–70
- vasculitis with prominent eye movement, background, 57
- vasculitis with prominent eye movement, types Cogan syndrome (CS), 61–65 Eales disease, 56–59 Susac syndrome (SS), 47–48 Vogt–Koyanagi–Harada disease (VKH), 51–53
- vasculopathies, non-inflammatory and stroke, moyamoya disease (MMD), 309–313
- vasculopathies, non-inflammatory and stroke carotid artery dissection, 326–330 cerebral amyloid angiopathy (CAA), 314–320 dolichoectasia and fusiform aneurysms, 321–325
- vasospastic conditions and stroke eclampsia during pregnancy, 299–303 migraines, 305–308

- reversible cerebral vasoconstriction syndrome (RCVS), 293–297
- venous occlusive conditions and stroke
- bone disorders, 336–341
- cerebral venous sinus thrombosis (CVST), 331–335
- Eagle syndrome, 343–348
- vessel-wall imaging (VWI) MR technique, 5, 8
- Vogt–Koyanagi–Harada disease (VKH) and stroke
- background, 51
- case presentation, 50
- classification, 52
- diagnostic algorithm, 51
- stages, 52
- treatment, 51, 52–53
- Wegener’s granulomatosis. *See* granulomatosis with polyangiitis (GPA) and stroke